An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis

Trial Profile

An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab in cystic fibrosis complicated with allergic bronchopulmonary aspergillosis

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 03 May 2016

At a glance

  • Drugs Omalizumab (Primary) ; Corticosteroids; Itraconazole
  • Indications Aspergillosis; Cystic fibrosis-associated respiratory tract infections
  • Focus Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 01 May 2016 This trial was completed in Belgium according to the European Clinical Trials Database.
    • 03 Apr 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top